These results suggest that although IL-1α might play an important role in the up-regulation of CD137 via the activation of NF-κB, cancer cells with K-Ras mutations seem to have at least another pathway via MAPK signaling to promote CD137 expression. This evidence concerns the gene KRAS and cancer.